Back to homepage

Haematology and Oncology

Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies

Authors: Sarah L Scarpace

Lung cancer is the third most commonly diagnosed cancer and the leading cause of cancer-related death in the United States. This paper provides an overview of drug therapy options for squamous cell NSCLC with a focus on the evidence and clinical application of the anti-PD1 therapies. A comparison of the dosing, administration, indications, and differences in the measurement of PD-L1 expression in the clinical trials of nivolumab and pembrolizumab is also provided.

More▸

An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries

Authors: Marco Turini, Vittoria Piovesana, Pierfrancesco Ruffo, Claudio Ripellino, Nazarena Cataldo

Inadequately treated, chemotherapy-induced nausea and vomiting (CINV) can lead to increased resource utilization and severely impair patients’ daily functioning and quality of life. The authors investigated the management of CINV episodes in three European health-care environments and estimate the direct costs associated with severe CINV episodes.

More▸

Diagnosis and management of lentigo maligna: a review

Authors: Julia M Kasprzak, Yaohul G Xu

In lentigo maligna, the ill-defined nature and potentially large size of lesions can pose significant diagnostic and treatment challenges. The goal of therapy is to cure the lesions in order to prevent development of invasive disease. In this article the authors describe techniques for surgical excision, which is currently the treatment of choice to achieve clear histological margins, and review the evidence for nonsurgical treatment modalities.

More▸

Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA

Authors: Allicia C Girvan, Gebra C Carter, Li Li, Anna Kaltenboeck, Jasmina Ivanova, Maria Koh, Jessi Stevens, Eleanor Hayes-Larson, Michael M Lahn

Glioblastoma (GB) treatment remains challenging because of recurrence and poorly defined treatment options after first-line therapy. To better understand real-world application of treatment paradigms and their impact on outcomes, the authors describe patterns of GB treatment, outcomes, and use of cancer-related healthcare resource in the USA.

More▸

One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA

Authors: Susan T Arthur, Joshua M Noone, Bryce A Van Doren, Debosoree Roy, Christopher M Blanchette

Cachexia is a condition characterized as a loss in body mass or metabolic dysfunction and it is associated with several prevalent chronic health conditions including many cancers, COPD, HIV, and kidney disease. Currently there is little research into cachexia and the objective of this article is to characterize cachexia patients, their healthcare utilisation, and associated hospitalization costs.

More▸